longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Adma Biologics

ADMA

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 12.86, within the reasonable range, cheaper than 71.26% of the time in the past 1 years, and the industry ranks 32/602, the industry Median -2.33.

12.86xP/E
$9.70Stock price
$0.75Earnings per share
12.86xP/E
Stock price$9.70Earnings per share$0.75

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
16.74x
Typical range
12.24x–20.49x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.43x42.44%$4.95B
ACADUSAcadia Pharma
11.52x73.45%$4.38B
PURRUSHyperliquid Strategies
10.77x85.25%$2.76B
AUPHUSAurinia Pharma
6.95x54.40%$2.18B
ADMAUSAdma Biologics
12.86x35.42%$2.17B
LKFTUSLakefront Biotherapeutics
2.89x86.19%$2.00B
ANABUSAnaptysbio
5.74x1,051.46%$1.50B
VORUSVor BioPharma
1.83x89.77%$1.15B
MGTXUSMeiraGTx
14.29x122.03%$1.13B
ABUSUSArbutus Pharma
6.24x533.09%$955.16M
RIGLUSRigel Pharma
2.79x83.91%$899.06M
BVNRYUSBavarian Nordic A/S
3.54x--$849.43M
IRWDUSIronwood Pharma
5.43x715.55%$705.57M
AGENUSAgenus
4.12x--$378.17M
CUVLUSClinuvel Pharmaceuticals
12.74x--$291.98M
QTTBUSQ32 Bio
8.42x162.23%$284.60M
PLXUSProtalix Biotherap
11.91x400.00%$225.60M
CGENUSCompugen
6.30x173.68%$221.65M
VXRTUSVaxart
3.02x328.57%$116.69M
RLYBUSRallybio
1.97x131.45%$89.54M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.